Application of Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma

References

• Susanibar-Adaniya S , BartaSK. 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. Am. J. Hematol.96(5), 617–629 (2021).
   PubMed Web of Science ®Google Scholar
• Alizadeh AA , EisenMB , DavisREet al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature403(6769), 503–511 (2000).
   PubMed Web of Science ®Google Scholar
• He MY , KridelR. Treatment resistance in diffuse large B-cell lymphoma. Leukemia35(8), 2151–2165 (2021).
   PubMed Web of Science ®Google Scholar
• Morton LM , WangSS , DevesaSS , HartgeP , WeisenburgerDD , LinetMS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood107(1), 265–276 (2006).
   PubMed Web of Science ®Google Scholar
• Iqbal J , NaushadH , BiCet al. Genomic signatures in B-cell lymphoma: how can these improve precision in diagnosis and inform prognosis? Blood Rev. 30(2), 73–88 (2016).
   PubMedGoogle Scholar
• Zhou L , ZhaoH , ShaoYet al. Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. J. Cancer12(18), 5423–5431 (2021).
   PubMed Web of Science ®Google Scholar
• Sun P , ChenC , XiaYet al. Mutation profiling of malignant lymphoma by next-generation sequencing of circulating cell-free DNA. J. Cancer10(2), 323–331 (2019).
   PubMed Web of Science ®Google Scholar
• Morin RD , MungallK , PleasanceEet al. Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing. Blood122(7), 1256–1265 (2013).
   PubMed Web of Science ®Google Scholar
• Gao H , WuB , JinH , YangW. A 6-lncRNA signature predicts prognosis of diffuse large B-cell lymphoma. J. Biochem. Mol. Toxicol.35(6), 1–12 (2021).
   Web of Science ®Google Scholar
• Lodhi N , TunM , NagpalPet al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget11(44), 4045–4073 (2020).
   PubMedGoogle Scholar
• Staton AD , KoffJL , ChenQ , AyerT , FlowersCR. Next-generation prognostic assessment for diffuse large B-cell lymphoma. Future Oncol.11(17), 2443–2457 (2015).
   PubMed Web of Science ®Google Scholar
• Young RM , ShafferAL3rd , PhelanJD , StaudtLM. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin. Hematol.52(2), 77–85 (2015).
   PubMed Web of Science ®Google Scholar
• Klanova M , SehnLH , Bence-BrucklerIet al. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood133(9), 919–926 (2019).
   PubMed Web of Science ®Google Scholar
• Seshadri MR , MelnickAM. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leuk. Lymphoma63(4), 789–798 (2022).
   PubMed Web of Science ®Google Scholar
• Knittel G , LiedgensP , KorovkinaD , PallaschCP , ReinhardtHC. Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. Eur. J. Haematol.97(6), 499–510 (2016).
   PubMed Web of Science ®Google Scholar
• Barton S , HawkesEA , WotherspoonA , CunninghamD. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?The Oncologist17(12), 1562–1573 (2012).
   PubMed Web of Science ®Google Scholar
• Dobashi A . Molecular pathogenesis of diffuse large B-cell lymphoma. J. Clin. Exp. Hematop.56(2), 71–78 (2016).
   PubMedGoogle Scholar
• Savage KJ , SlackGW , MottokAet al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood127(18), 2182–2188 (2016).
   PubMed Web of Science ®Google Scholar
• Kano R , MasaieH , HinoAet al. Pure intravascular recurrence of CD5-positive diffuse large B-cell lymphoma primarily arising from the nasal cavities. Diagn. Pathol.13(1), 46 (2018).
   PubMedGoogle Scholar
• Durani U , AnsellSM. CD5+ diffuse large B-cell lymphoma: a narrative review. Leuk. Lymphoma62(13), 3078–3086 (2021).
   PubMed Web of Science ®Google Scholar
• Miyazaki K , AsanoN , YamadaTet al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica105(9), 2308–2315 (2020).
   PubMed Web of Science ®Google Scholar
• Xu Y , SunW , LiF. De Novo CD5(+) Diffuse large B-cell lymphoma: biology, mechanism, and treatment advances. Clin. Lymphoma Myeloma Leuk.20(10), e782–e790 (2020).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH . Diagnosis of ‘double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology2014(1), 90–99 (2014).
   PubMedGoogle Scholar
• Mehta A , VermaA , GuptaG , TripathiR , SharmaA. Double hit and double expresser diffuse large B cell lymphoma subtypes: discrete subtypes and major predictors of overall survival. Indian J. Hematol. Blood Transfus.36(4), 627–634 (2020).
   PubMed Web of Science ®Google Scholar
• Grzegorz S . Nowakowski M, And Myron S. Czuczman, Md. ABC, GCB, and double-hit diffuse large B-cell lymphoma: does subtype make a difference in therapy selection?Oncology Educational Book (35), e449–e457 (2015).
   Google Scholar
• Li J , LiuX , YaoZ , ZhangM. High-grade B-cell lymphomas, not otherwise specified: a study of 41 cases. Cancer Manag. Res.12, 1903–1912 (2020).
   PubMed Web of Science ®Google Scholar
• Ma Z , NiuJ , CaoYet al. Clinical significance of ‘double-hit’ and ‘double-expression’ lymphomas. J. Clin. Pathol.73(3), 126–138 (2020).
   PubMed Web of Science ®Google Scholar
• Yi W , BingX , YizhuoZ. Molecular diagnosis and treatment of relapsed/refractory diffuse large B-cell lymphoma. J. Exp. Hematol.26(2), 603–608 (2018).
   Google Scholar
• Schmitz R , WrightGW , HuangDWet al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med.378(15), 1396–1407 (2018).
   PubMed Web of Science ®Google Scholar
• Wright GW , HuangDW , PhelanJD , CoulibalyZA. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell37(4), 551–568 e514 (2020).
   PubMed Web of Science ®Google Scholar
• Wei X , JinhuaL. Advances in novel genotyping and molecular targeting therapy for diffuse large B cell lymphoma. J. Clin. Hematol.33(9), 594–598 (2020).
   Google Scholar
• Frontzek F , LenzG. Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications. Expert Rev. Clin. Pharmacol.12(11), 1059–1067 (2019).
   PubMed Web of Science ®Google Scholar
• Karmali R , GordonLI. Molecular subtyping in diffuse large B cell lymphoma: closer to an approach of precision therapy. Curr. Treat Options Oncol.18(2), 11 (2017).
   PubMed Web of Science ®Google Scholar
• Chapuy B , StewartC , DunfordAJ. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med.24(5), 679–690 (2018).
   PubMed Web of Science ®Google Scholar
• Zhou Z , SehnLH , RademakerAWet al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood123(6), 837–842 (2014).
   PubMed Web of Science ®Google Scholar
• Lacy SE , BarransSL , BeerPAet al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood135(20), 1759–1771 (2020).
   PubMed Web of Science ®Google Scholar
• International non-Hodgkin’s lymphoma prognostic factors Project . A predictive model for aggressive non-Hodgkin’s lymphoma. N. Engl. J. Med.329(14), 987–994 (1993).
   PubMed Web of Science ®Google Scholar
• Ruppert AS , DixonJG , SallesGA , WallA. International prognostic indices in diffuse large B-cell lymphoma (DLBCL): a comparison of IPI, R-IPI and NCCN-IPI. Blood135(23), 2041–2048 (2019).
   Web of Science ®Google Scholar
• Montalban C , Diaz-LopezA , DlouhyI. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI. Br. J. Haematol.176(6), 918–928 (2017).
   PubMed Web of Science ®Google Scholar
• Schmitz N , ZeynalovaS , NickelsenMet al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol.34(26), 3150–3156 (2016).
   PubMed Web of Science ®Google Scholar
• Wei X , HaoX , ZhouLet al. The international staging system improves the IPI risk stratification in patients with diffuse large B-cell lymphoma treated with R-CHOP. Sci. Rep.7(1), 13592 (2017).
   PubMedGoogle Scholar
• Seo S , HongJY , YoonSet al. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era. Oncotarget7(47), 76934–76943 (2016).
   PubMedGoogle Scholar
• Junshik Hong SJK , MyungHee C. Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Pathology50(1), 74–87 (2017).
   PubMedGoogle Scholar
• Reddy A , ZhangJ , DavisNS , MoffittAB. Genetic and functional drivers of diffuse large B cell lymphoma. Cell172(2), 481–494 (2017).
   Google Scholar
• Kurtz DM , SchererF , JinMCet al. Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma. J. Clin. Oncol.36(28), 2845–2853 (2018).
   PubMed Web of Science ®Google Scholar
• Younes A , SehnLH , JohnsonPet al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J. Clin. Oncol.37(15), 1285–1295 (2019).
   PubMed Web of Science ®Google Scholar
• Wilson WH , WrightGW , HuangDWet al. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell39(12), 1643–1653.e1643 (2021).
   PubMed Web of Science ®Google Scholar
• Dunleavy K , PittalugaS , CzuczmanMSet al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood113(24), 6069–6076 (2009).
   PubMed Web of Science ®Google Scholar
• Chiappella A , VitoloU. Lenalidomide in diffuse large B-cell lymphomas. Adv. Hematol.2012, 498342 (2012).
   PubMedGoogle Scholar
• Czuczman MS , TrnenyM , DaviesAet al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin. Cancer Res.23(15), 4127–4137 (2017).
   PubMed Web of Science ®Google Scholar
• Flinn IW , KahlBS , LeonardJPet al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood123(22), 3406–3413 (2014).
   PubMed Web of Science ®Google Scholar
• Shortt J , MartinBP , NewboldAet al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood121(15), 2964–2974 (2013).
   PubMed Web of Science ®Google Scholar
• Johnston PB , LaplantB , McphailEet al. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial. Lancet Haematol.3(7), e309–e316 (2016).
   PubMed Web of Science ®Google Scholar
• Moffitt AB , DaveSS. Clinical applications of the genomic landscape of aggressive non-Hodgkin lymphoma. J. Clin. Oncol.35(9), 955–962 (2017).
   PubMed Web of Science ®Google Scholar
• Lam LT , WrightG , DavisREet al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood111(7), 3701–3713 (2008).
   PubMed Web of Science ®Google Scholar
• Younes A , RomagueraJ , FanaleMet al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J. Clin. Oncol.30(33), 4161–4167 (2012).
   PubMed Web of Science ®Google Scholar
• Sarkozy C , MorschhauserF , DuboisSet al. A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. Clin. Cancer Res.26(13), 3145–3153 (2020).
   PubMed Web of Science ®Google Scholar
• Sehn LH , HerreraAF , FlowersCRet al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J. Clin. Oncol.38(2), 155–165 (2020).
   PubMed Web of Science ®Google Scholar
• Terui Y , RaiS , IzutsuKet al. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci.112(7), 2845–2854 (2021).
   PubMed Web of Science ®Google Scholar
• Kalakonda N , MaerevoetM , CavalloFet al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol.7(7), e511–e522 (2020).
   PubMed Web of Science ®Google Scholar
• Alkodsi A , CerveraA , ZhangKet al. Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes. Leukemia33(11), 2662–2672 (2019).
   PubMed Web of Science ®Google Scholar
• Trabucco SE , SokolES , MaundSLet al. Prediction and characterization of diffuse large B-cell lymphoma cell-of-origin subtypes using targeted sequencing. Future Oncol.17(31), 4171–4183 (2021).
   PubMed Web of Science ®Google Scholar